DURHAM, N.C. A large federal grant awarded to Duke University will fund a highly focused program to discover how to induce the precise immune factors needed for effective vaccines against HIV.
Barton Haynes, M.D., will be the Duke director of the seven-year grant for the Duke Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery (CHAVI-ID).
Haynes previously led the original Center for HIV/AIDS Vaccine Immunology (CHAVI) consortium, the grant for which just ended in June 2012.
For its role in the new CHAVI-ID program, Duke will receive $19.9 million for the first year beginning this month, according to the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Scripps Research Institute was also selected as a second center to receive CHAVI-ID grant funding.
The CHAVI-ID initiative overall may receive as much as $186 million or more over seven years. Duke may receive more than $139 million in total over the same time period.
"Duke is deeply honored to be selected again, as we now build on all the progress made in the initial CHAVI grant and now focus the effort on design of immunogens capable of preventing HIV transmission and protecting people worldwide," said Victor J. Dzau, M.D., Chancellor for Health Affairs and CEO of Duke University Health System.
NIAID originally established CHAVI in response to recommendations of the Global HIV Vaccine Enterprise, a virtual consortium endorsed by world leaders at a G-8 summit in June 2004.
"We were privileged to have the CHAVI grant over the past seven years, and the work in this consortium helped us understand what needed to be done to make a successful AIDS vaccine," said Haynes, who is also director of the Duke Human Vaccine Institute and the Frederic M. Hanes Professor of Medicine and Immunology. "The CHAVI-Immunogen Discovery grant will be used to learn how to do what we need t
|Contact: Mary Jane Gore|
Duke University Medical Center